Currently, there are more than 5 million people in the U.S. diagnosed with Alzheimer’s disease. By 2050, that number could nearly triple, to 14 million people. But Budd Haeberlein, vice president of clinical development at Biogen, believes they can deliver a treatment to the millions of Alzheimer’s disease patients and their families who are waiting. He shares why he believes his optimism is rooted in the science, which continues to evolve and advance right before our eyes. You can read the entire article HERE.